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Glioblastoma is a fatal primary malignant brain tumor, and the 5-year survival rate of
treated glioblastoma patients still remains <5%. Considering the sustained development
of metastasis, tumor recurrence, and drug resistance, there is an urgent need for the novel
therapeutic approaches to combat glioblastoma. Trivalent arsenic derivative (arsenite,
AsIII) with remarkable clinical efficacy in leukemia has been shown to exert cytocidal effect
against glioblastoma cells. Gamabufotalin, an active bufadienolide compound, also shows
selective cytocidal effect against glioblastoma cells, and has been suggested to serve as a
promising adjuvant therapeutic agent to potentiate therapeutic effect of conventional
anticancer drugs. In order to gain novel insight into therapeutic approaches against
glioblastoma, the cytotoxicity of AsIII and gamabufotalin was explored in the human
glioblastoma cell lines U-87 and U-251. In comparison with U-251 cells, U-87 cells were
highly susceptible to the two drugs, alone or in combination. More importantly, clinically
achieved concentrations of AsIII combined with gamabufotalin exhibited synergistic
cytotoxicity against U-87 cells, whereas showed much less cytotoxicity to human
normal peripheral blood mononuclear cells. G2/M cell cycle arrest was induced by each
single drug, and further augmented by their combination in U-87 cells. Downregulation of
the expression levels of cdc25C, Cyclin B1, cdc2, and survivin was observed in U-87 cells
treated with the combined regimen and occurred in parallel with G2/M arrest.
Concomitantly, lactate dehydrogenase leakage was also observed. Intriguingly,
SB203580, a specific inhibitor of p38 MAPK, intensified the cytotoxicity of the
combined regimen in U-87 cells, whereas wortmannin, a potent autophagy inhibitor,
significantly rescued the cells. Collectively, G2/M arrest, necrosis and autophagy
appeared to cooperatively contribute to the synergistic cytotoxicity of AsIII and
gamabufotalin. Given that p38 MAPK serves an essential role in promoting
glioblastoma cell survival, developing a possible strategy composed of AsIII,March 2021 | Volume 11 | Article 6289141
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designed to combat glioblastoma.Keywords: arsenite, gamabufotalin, glioblastoma, cell cycle arrest, p38 MAPK, autophagy, lactate dehydrogenase,
combination therapyINTRODUCTION
Glioblastoma is one of the most common and lethal form of
primary brain tumors, and characterized by fast infiltration,
rapid growth, and resistance to conventional therapies (1, 2).
Despite advances in the understanding of the nature of the
molecular events associated with disease development and
progression, the 5-year survival rate of treated glioblastoma
still remains <5% (3). The median survival time for patients
was only 14.6 to 20.9 months (4, 5). Considering the sustained
development of metastasis, tumor recurrence, and drug
resistance, there is an urgent need for the novel therapeutic
approaches to combat glioblastoma.
It has been reported that trivalent arsenic derivatives
(arsenite, AsIII) such as arsenic trioxide (As2O3) show superior
therapeutic efficacy for acute promyelocytic leukemia (APL)
patients (6, 7). These findings further opened the possibility of
using AsIII for other malignancies (8, 9). Several research groups
including us have performed detailed systematic studies on the
metabolites of AsIII in APL patients (6, 7, 10, 11). We previously
carried out a study of speciation of As2O3 in cerebrospinal fluid
(CSF) samples from APL patients, and demonstrated for the first
time that both inorganic arsenic and methylated metabolites
existed in CSF, indicating that AsIII is capable of penetrating into
blood-brain barrier (10). In addition, AsIII has been reported to
show cytotoxicity toward glioblastoma cells through cell cycle
arrest and autophagic cell death (12–14). These previous
observations raise the possibility of utilizing AsIII to treat
patients with glioblastoma.
Natural products have been being received increased
attention, due to their great potential in various cancer
therapies. Bufadienolides are the major effective constituents of
cinobufacini (also known as Huachansu), a well-known Chinese
medicine that comes from the dried skin of Bufo bufo gargarizans
Cantor, and cinobufacini has been employed to treat patients
with different types of cancers such as hepatoma, gallbladder
carcinoma, and lung cancer (15–17). We previously clarified that
active bufadienolide compounds such as gamabufotalin and
arenobufagin showed selective cytocidal effects against
intractable cancer cells such as glioblastoma, but minimal
effects on human normal peripheral blood mononuclear cells
(PBMCs) (18) and mouse primary astrocytes (19). Notably,
nearly non-toxic gamabufotalin concentrations on PBMCs
effectively reduced the percentages of T-regulatory cells (Treg)
cells (18), which has been characterized to play a critical role in
limiting antitumor immune response and promoting
immunological ignorance in cancer (20–22), suggesting the
capability of gamabufotalin to enhance antitumor immunity.
Additionally, bufadienolides have been demonstrated to enhance
therapeutic efficacy of different types of cancer treatment (23,2
24). These previous observations thus suggest that bufadienolides
including gamabufotalin may serve as a promising adjuvant
therapeutic agent to potentiate therapeutic effect of
convent iona l ant icancer drugs . However , whether
gamabufotalin can sensitize glioblastoma cells to AsIII has not
yet been evaluated.
It has been demonstrated that cell cycle arrest, necrotic and
autophagic cell death contribute to cytocidal effect of
chemotherapeutic agents (19, 25–27). Cell cycle is coordinately
and tightly regulated by the cyclin-dependent kinases (CDKs)
and their associated regulatory cyclins (CDK/Cyclin complexes)
(28, 29). Cdc25C has been demonstrated to play an important
role in G2/M transitions of the cell cycle by activating cdc2/
Cyclin B1 (28, 29). Survivin has been associated with increased
malignancy of human gliomas, and considered to play vital roles
in therapeutic resistance of primary glioblastoma cells (30). In
addition, p38 kinase, a member of the mitogen-activated protein
kinases (MAPKs) family, has been considered to be positively
related to diverse cellular processes including cell cycle arrest and
cell death signaling (31–33). Inversely, a novel prosurvival role of
p38 MAPK has been demonstrated in human cancer cells such as
glioblastoma cells (19, 34–36). Despite this, the molecular events
underlying the potential cytotoxic effects caused by AsIII and
gamabufotalin, alone or in combination, against glioblastoma
cells remain to be seen.
In the current study, in order to provide a novel insight into
approach designed to combat glioblastoma, the cytotoxicity of
AsIII and gamabufotalin, alone or in combination, was
investigated in the human glioblastoma cell lines U-87 and U-
251 by focusing on proliferation inhibition associated with cell
cycle arrest as well as cell death. PBMCs were also used to explore
whether clinically achieved concentrations of AsIII in
combination with gamabufotalin show cytotoxic selectivity for
cancer cells, rather than normal cells. Key regulatory molecules
involved in cell cycle and cell death were investigated to further
elucidate cytotoxic mechanisms. Whether p38 MAPK is
implicated in AsIII plus gamabufotalin-mediated cytocidal
effects in U-87 cells was also investigated by using its specific
inhibitor, SB203580.MATERIALS AND METHODS
Materials
Sodium arsenite (NaAsO2, As
III) (>99% purity) and
gamabufotalin (≥98% purity) were purchased from Tri
Chemical Laboratories (Yamanashi, Japan) and Baoji Herbest
Bio-Tech Co., Ltd. (Baoji, China), respectively. Wortmannin, a
potent autophagy inhibitor, 2,3-bis(2-methoxy-4-nitro-5-March 2021 | Volume 11 | Article 628914
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hydroxide (XTT), propidium iodide (PI), proteinase K, and
ribonuclease A (RNaseA) were purchased from Merck KGaA
(Sigma-Aldrich; Darmstadt, Germany). Dulbecco’s modified
Eagle’s medium (DMEM) and phenazine methosulfate (PMS)
were purchased from Wako Pure Chemical Industries (Osaka,
Japan). Both SB203580, a specific inhibitor of p38 MAPK, and its
negative control SB202474 were purchased from Merck KGaA.
Fetal bovine serum (FBS) was obtained from Nichirei
Biosciences (Tokyo, Japan). Can Get Signal® Immunoreaction
Enhancer Solution was purchased from Toyobo Co., Ltd.
(Osaka, Japan).
Cell Culture and Treatment
Human glioblastoma cell lines U-87 and U-251 were obtained
from the American Type Culture Collection (ATCC, Manassas,
VA, USA) and cultured in DMEM supplemented with 10% heat-
inactivated FBS and antibiotics [100 U/ml of penicillin and 100
mg/ml of streptomycin (Wako Pure Chemical Industries)] in a
humidified 5% CO2 atmosphere at 37°C. Human peripheral
blood mononuclear cells (PBMCs) were isolated from healthy
volunteers using lymphocyte separation solution (d = 1.077)
(Nacalai Tesque, Inc., Kyoto, Japan) according to the method
previously described (18, 37). Briefly, 3 ml of heparinized blood
was loaded on 3 ml of lymphocyte separation solution. After
centrifugation at 400 × g for 30 min at room temperature, the
opaque interface containing PBMCs was transferred to a clean
centrifuge tube and washed three times with PBS. PBMCs were
also cultured in RPMI-1640 medium supplemented with 10%
heat-inactivated FBS, 100 U/ml of penicillin and 100 mg/ml of
streptomycin in a humidified 5% CO2 atmosphere at 37°C. The
cell density of PBMCs was adjusted to 5 × 105 cells/ml prior to
the treatments. This study has been approved by the IRB
committee of Tokyo University of Pharmacy and Life Sciences.
A written informed consent was obtained from all healthy
volunteers. All methods were performed in accordance with
the relevant guidelines and regulations. In experiments using
inhibitors, U-87 cells were treated with respective inhibitor at the
indicated concentrations for 30 min prior to treatment with
indicated concentrations of AsIII in combination with
gamabufotalin, in the presence or absence of respective
inhibitor for an additional 48 h.
Cell Viability Assay
Following treatment for 48 h with various indicated
concentrations of AsIII and gamabufotalin, alone or in
combination, cell viability was measured by the XTT assay as
described previously (36, 38). Relative cell viability was expressed
as the ratio of the absorbance at 450 nm of each treatment group
against those of the corresponding untreated control group. Data
are shown as mean ± standard deviation (SD) from more than
three independent experiments. The IC50 value of the drug was
calculated using GraphPad Prism®6 software. In order to
evaluate whether the two drugs generated synergistic,
antagonistic, or additive effects, a combination index (CI) was
determined as reported previously, using the computer software
ComboSyn (Combosyn Inc. NJ, USA) for drug combinationsFrontiers in Oncology | www.frontiersin.org 3and for general dose–effect analysis, which was developed by
Chou (39, 40). The effect of the combination treatment was
defined as a synergistic effect if CI < 1, an additive effect if CI = 1
or an antagonistic effect if CI > 1 (27, 41).
Cell Cycle Analysis
After treatment with various indicated concentrations of AsIII
and gamabufotalin, alone or in combination, for 48 h, cell cycle
analysis was performed using a FACSCanto™ flow cytometer
(Becton Dickinson, CA, USA) according to the methods reported
previously (19, 27, 37). Briefly, cells were washed twice with cold
PBS, fixed with 1% paraformaldehyde/PBS on ice for 30 min,
washed twice again with cold PBS, permeabilized in 70% (v/v)
cold ethanol, and kept at −20°C for at least 4 h. Cell pellets were
then washed twice with cold PBS after centrifugation (430 × g for
5 min at 4°C) and incubated with 0.25% Triton-X 100 for 5 min
on ice. After centrifugation (430 × g for 5 min at 4°C) and
washing with PBS, cells were resuspended in 500 µl of PI/RNase
A/PBS (5 µg/ml of PI and 0.1% RNase A in PBS) and incubated
for 30 min in the dark at room temperature. A total of 10,000
events were acquired, and FACSDiva™ software (v6.0; BD
Biosciences) and ModFit LT™ v3.0 (Verity Software House,
Inc., Topsham, ME, USA) were used to calculate the number of
cells at G2/M phase fraction.
Western Blot Analysis
For preparation of the protein samples, cell pellets (1–2 × 106
cells per 110 ml buffer) were suspended in Laemmli buffer
containing 100 mM DTT, 2 mg/ml leupeptin, 2 mg/ml
aprotinin, 1 mg/ml pepstatin, and 1 mM PMSF. Cell
suspensions were sonicated (Qsonica, LLC, Newtown, CT,
USA) with 10 short bursts of 2 s followed by intervals of 2 s
for cooling. The suspensions were then kept in an ice bath.
Sonicated cells were heated in 95°C for 5 min, and then
centrifuged at 13,000 × g for 15 min at 4°C. Protein
concentrations of the supernatant were determined by
Bradford’s method using the protein assay dye reagent (Bio-
Rad Laboratories, Inc.) according to the manufacturer’s
instructions, using BSA as standard. Western blot analysis was
carried out according to a method previously described (37, 41).
Briefly, protein samples (10–20 mg protein/lane) were separated
on a sodium dodecyl sulfate polyacrylamide gel electrophoresis,
followed by transferring to a polyvinylidene difluoride (PVDF)
membrane, which was then blocked with 5% skim milk/PBST
(PBS containing 0.5% Tween-20) for 1 h at room temperature.
Protein bands were detected using the following primary
antibodies: Mouse anti-human b-actin (1:5,000 dilution; cat.
no. A-5441; Sigma-Aldrich; Merck KGaA, Darmstadt,
Germany), rabbit anti-human cdc25C (1:1,000 dilution; cat.
no. 4688), mouse anti-human Cyclin B1 (1:2,000 dilution; cat.
no. 4135), mouse anti-human cdc2 (1:1,000 dilution; cat. no.
9116), mouse anti-human survivin (1:1000 dilution; cat. no.
2802), rabbit anti-human phospho-p38 (Thr180/Tyr182,
1:1,000 dilution; cat. no. 9211), and p38 (1:1,000 dilution; cat.
no. 9212; all from Cell Signaling Technology, Inc., Danvers, MA,
USA). PVDF membranes containing blotted protein bands were
incubated overnight with the respective primary antibody at 4°C,March 2021 | Volume 11 | Article 628914
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peroxidase-conjugated secondary antibody (anti-mouse IgG,
1:3,000 dilution, cat. no. A5906; anti-rabbit IgG, 1:3,000
dilution, cat. no. A0545; both from Sigma-Aldrich; Merck
KGaA) for 1 h at room temperature, and then detected with
an enhanced chemiluminescence (ECL) analysis system
(Amersham Pharmacia Biotech, Buckinghamshire, UK).
Relative amounts of the immunoreactive proteins were
calculated from the density of the gray level on a digitized
image using a program, NIH Image 1.60.
Lactate Dehydrogenase (LDH) Assay
Following treatment for 48 h with indicated concentrations of
AsIII and gamabufotalin, alone or in combination, LDH leakage
from U-87 cells was measured using a LDH cytotoxicity
detection kit (Wako Pure Chemical Industry) according to the
method previously described with slight modifications (19, 36).
Briefly, culture medium served as the negative control (NC).
Culture supernatants (S) were collected by centrifugation at 450 × g
for 5 min at 4°C and stored at −80°C until use. Cultured cells
without treatment were lysed in the culture medium containing
0.2% Tween 20, and mixed aggressively using a vortex mixer,
followed by the centrifugation at 12,000 × g for 10 min at 4°C and
the cell lysate was used as the positive control (PC). In order to
avoid an influence of Tween 20, culture medium containing 0.2%
Tween 20 served as the negative control for PC and was referred to
as NCT. Samples were diluted 16-fold with PBS and 50 ml of the
diluted solution was transferred into wells of a 96-well plate. LDH
activities were determined by adding 50 ml of “reaction reagent”
from the kit, followed by incubation at room temperature for
30 min. The reaction was stopped by the addition of 100 ml of
“stopping solution” provided with the kit at room temperature, and
the absorbance at 560 nm was measured with a microplate reader
(EMax®Plus, Molecular Devices, CA, USA). Cell damage was
calculated as a percentage of LDH leakage from damaged cells
using the following formula: LDH leakage (%) = (S-NC)/(PC-
NCT) × 100. Data are shown as means and SD from three
independent experiments.
Statistical Analysis
Experiments were independently repeated three times, and the
results were shown as the means ± standard deviation (SD) of
three assays. Statistical analysis was conducted using one-way
ANOVA followed by Dunnett’s post hoc test. A probability
level of p < 0.05 was considered to indicate a statistically
significant difference.RESULTS
Cytotoxic Effects of AsIII and
Gamabufotalin Against Human
Glioblastoma Cell Lines U-87 and U-251
Although treatment with various concentrations of AsIII for 48 h
exhibited cytotoxic activities against U-87 and U-251 cells in a
similar dose-dependent manner, the IC50 value of As
III in U-87Frontiers in Oncology | www.frontiersin.org 4was approximately only one-fourth of that in U-251 cells (4.4 ± 1.1
µM in U-87; 18.2 ± 3.3 µM in U-251; p < 0.001) (Figures 1A, B).
Treatment with gamabufotalin for 48 h also exhibited a dose-
dependent cytotoxicity against U-87 cells with IC50 value of 64.8 ±
6.8 nM (Figure 1C). Interestingly, an untypical sigmoid growth
inhibition model was observed in U-251 cells treated with
gamabufotalin for 48 h, since the growth inhibition rates of the
drug at concentrations >100 nM were very close to each other
(Figure 1D). The IC50 value of gamabufotalin in U-87 cells was 2.5
times less than that in U-251 cells (64.8 ± 6.8 nM in U-87; 162 ±
44.3 nM in U-251; p < 0.05) (Figures 1C, D). These results
indicated that U-87 cells were more sensitive to the cytotoxicity of
both AsIII and gamabufotalin, compared to U-251 cells.
G2/M Arrest-Inducing Activity of As
III and
Gamabufotalin in U-87 and U-251 Cells
Treatment with various concentrations of AsIII for 48 h exhibited
a dose-dependent biphasic effect on G2/M arrest of U-87 cells, in
which G2/M arrest-inducing activity of As
III was first observed at
the concentration starting from 1 mM AsIII, and reached the
maximum at the concentrations of 3 mM AsIII, then declined
with increasing concentrations of AsIII (Figure 2A and
Supplementary Figure 1). In comparison, only relatively high
concentrations of AsIII (20 and 30 mM) prominently induced
G2/M arrest in U-251 cells (Figure 2B and Supplementary
Figure 2). Notably, a sub-G1 peak was concomitantly detected
following treatment with relatively high concentrations of AsIII
(20 and 30 mM) in U251 cells (Supplementary Figures 2E, F).
Exposure to gamabufotalin for 48 h also caused G2/M arrest of
U-87 cells in a dose-dependent manner, and its G2/M arrest-
inducing activity reached a plateau at the concentrations of 100
nM (Figure 2C and Supplementary Figure 3). In comparison,
the G2/M arrest-inducing activity of gamabufotalin in U-251
cells was observed at the concentrations starting from 100 nM,
and reached a plateau at the concentrations of 200 nM (Figure
2D and Supplementary Figure 4).
Synergistic Cytotoxic Effect of AsIII and
Gamabufotalin in Glioblastoma Cell Line
U-87 but Not U-251
In order to evaluate if the two drugs generated synergistic,
antagonistic, or additive effects, based upon the IC50 values of
each drug, the two-drug combination was determined according
to the median-effect method of Chou (39, 40). As shown in
Figure 3A, the combined treatment was significantly more
cytotoxic than either drug alone in U-87 cells, and the values
of combination index (CI) were <1 (Table 1), indicating the two
drugs worked in a synergistic manner. However, similar
combination effect was not observed in U-251 cells (Figure
3B), reconfirming that U-87 was highly susceptible to the
combined regimen in comparison to U-251.
Considering that G2/M arrest was significantly induced by 1
and 2 mM AsIII (Figure 2A), both of which were considered as
clinically achieved concentrations of AsIII, and by 20 and 50 nM
gamabufotalin (Figure 2C), respectively, the cytotoxicity of
relatively low concentrations of AsIII (1 and 2 mM) andMarch 2021 | Volume 11 | Article 628914
Yuan et al. Cytotoxicity of AsIII+Gamabufotalin in U-87gamabufotalin (20 and 50 nM), alone or in combination, were
further explored in U-87 cells in detail. As shown in Figure 3C, a
modest but statistically significant decrease in cell viability was
observed in the cells following treatment for 48 h with each single
drug, and was further significantly intensified by their
combination. The values of combination index (CI) of all
combined treatment group were <1 (Table 2), indicating that
the two drugs worked in a synergistic manner even at their
relatively low concentrations. In comparison, under the same
treatment conditions, only a modest growth inhibition (less than
15%) was induced by each single drug in PBMCs (Figure 3D).
Furthermore, as compared to the growth inhibition rates ranging
from 45 to 50% in U-87 cells, much lower inhibition rates
ranging from 15 to 27% were observed in PBMCs (Figures 3C,
D), indicating selective cytocidal effect of the combined regimen.Effects of Relatively Low Concentrations
of AsIII in Combination With Gamabufotalin
on G2/M Arrest and the Expression Level
of Cell Cycle Related-Proteins in U-87
Cells
Consistent with results in Figures 2A, C, a dose-dependent G2/
M arrest was induced by each single drug, and was further
significantly augmented by 1 mM AsIII in combination with 20
and 50 nM gamabufotalin, respectively (Figure 4A andFrontiers in Oncology | www.frontiersin.org 5Supplementary Figure 5). Probably due to the high potency of
G2/M arrest-inducing activity of 2 mM AsIII, only a slight
enhancement in its activity was observed by the addition of 20
or 50 nM gamabufotalin (Figure 4A).
As shown in Figure 4B, in comparison to control group, a
clear downregulation of the expression of cdc25C was induced by
each single drug, and was further significantly intensified by their
combination following treatment for 48 h with AsIII (1, 2 mM)
and gamabufotalin (20, 50 nM), alone or in combination. A
modest but significant downregulation of the expression level of
Cyclin B1 was induced by 2 mM AsIII, and 20, 50 nM
gamabufotalin, respectively. A slight decrease of the expression
level of Cyclin B1 induced by 1 mM AsIII was significantly
intensified by the addition of 50 nM gamabufotalin. Similar
phenomena were also observed in the cells treated with 2 mM
AsIII combined with 50 nM gamabufotalin. Moreover, a trend
towards a downregulation of Cyclin B1 was observed in the
treatment of 1 or 2 mM AsIII combined with 20 nM
gamabufotalin, although there was no significant difference
between each single drug and their combination. In addition,
the clinically achieved concentrations of AsIII (1 and 2 µM) also
modestly and significantly suppressed the expression level of
survivin. In comparison, the addition of either 20 nM or 50 nM
gamabufotalin appeared to strongly downregulate the expression
of survivin. Of note, as compared to 20 nM gamabufotalin, the
addition of 50 nM gamabufotalin more efficiently intensifiedA B
C D
FIGURE 1 | Respective cytotoxic effect of AsIII and gamabufotalin against human glioblastoma cell lines U-87 and U-251. Cell viability was determined by XTT assay
after the treatment with various concentrations of AsIII alone [(1, 3, 5, 10, and 30 µM) (A); (3, 5, 10, 30 and 100 µM) (B)], gamabufotalin alone [4, 20, 50, 100, 200,
500, and 1,000 nM (C, D)] for 48 h. Relative cell viability was calculated as the ratio of the absorbance at 450 nm of each treatment group against those of the
corresponding untreated control group. Data are shown as the means ± SD (n ≥ 3). As, AsIII.March 2021 | Volume 11 | Article 628914
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drug (except for 1 mM AsIII) modestly and significantly
suppressed the expression of cdc2, and their combination
slightly strengthened the suppression.
Enhanced LDH Release in U-87 Cells
Treated With Relatively Low
Concentrations of AsIII Combined With
Gamabufotalin
The release of LDH provides an accurate measure of the cell
membrane integrity and cell viability (27, 36). Following
treatment with relatively low concentrations of AsIII (1 and 2 mM)
and gamabufotalin (20 and 50 nM), alone or in combination, for
48 h, LDH leakage analysis was conducted to examine whether the
combined treatment directly affected cell membrane integrity. As
shown in Figure 5, a measurable level of LDH leakage was induced
by each single drug except for 20 nM gamabufotalin. The exposure
of2mMAsIII in combinationwitheither 20or50nMgamabufotalin
further prominently enhanced the LDH leakage. Additionally, a
slight but significant increase in the LDH leakage was induced by 1
mMAsIII combined with 20 nM gamabufotalin in comparison with
each single drug. Intriguingly, similar phenomenon was notFrontiers in Oncology | www.frontiersin.org 6observed in the treatment of 1 mM AsIII in combination with 50
nM gamabufotalin, which is might be a result of relatively high
efficiency of 50 nM gamabufotalin itself to induce LDH leakage.
Prosurvival Role of p38 MAPK in the
Cytotoxicity of U-87 Cells Treated With the
Combination of AsIII and Gamabufotalin
Since we have recently demonstrated a prosurvival role for p38
MAPK in glioblastoma cells treated with active bufadienolide
compounds including gamabufotalin (19, 36), the activation of
p38 MAPK and its possible role associated with cell viability were
explored inU-87cells following the treatmentwith the combination
of either relatively high or low concentrations of AsIII and
gamabufotalin. As shown in Figure 6, the expression of phospho-
p38 (p-p38) was modestly and clearly upregulated by
gamabufotalin and AsIII (3.3, 5 mM), respectively, and further
strengthened by the combination of 3.3 mM AsIII + 40 nM
gamabufotalin, and 5 mM AsIII + 60 nM gamabufotalin. A
dramatic upregulation of the expression level of p-p38 was
induced by 7.5 mM AsIII, and the further enhancement was not
observed by the addition of 90 nM gamabufotalin. Moreover, no
alteration of the expression level of p38 was observed regardless ofA B
C D
FIGURE 2 | Respective G2/M arrest-inducing activity of As
III and gamabufotalin in U-87 and U-251 ells. Following treatment for 48 h with various concentrations of
AsIII (1, 2, 3, 4, 5, 10, 20, and 30 µM) alone (A, B), gamabufotalin (4, 20, 50, 100, 200, and 500 nM) alone (C, D), cell cycle profiling was performed by FACSCanto
flow cytometer as described under Materials and Methods. A total of 10,000 events were acquired, and FACSDiva™ software and ModFit LT™ v3.0 were used to
calculate the number of cells at G2/M phase fraction. Results are shown as the means ± SD (n ≥ 3). Significant difference between control and treatment groups are
shown (*p < 0.05; §p < 0.001; ‡p < 0.0001 vs. control). As, AsIII.March 2021 | Volume 11 | Article 628914
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shown in Figure 7A, in comparison to a significant upregulation of
p-p38 expression triggeredby relatively high concentrations ofAsIII
and gamabufotalin, almost no alteration of p-p38 expression wasFrontiers in Oncology | www.frontiersin.org 7observed in the cells following the treatment with 1 mM AsIII
combined with 20 and 50 nM gamabufotalin, respectively. In
addition, only a slight increase in the expression level of p-p38
was observed in the cells following the treatment with 2 mM AsIII
combinedwith20or50nMgamabufotalin incomparisonwitheach
single drug. Again, almost no alteration of the expression level of
p38 was observed regardless of treatment with each single drug
alone or their combination.
In order to clarify whether p38 MAPK is directly involved in
the cytotoxicity of the combined regimen, alterations of the cell
viability were determined in U-87 cells following treatment for
48 h with the combination of AsIII and gamabufotalin (2 mM
AsIII + 50 nM gamabufotalin; 3.3 mM AsIII + 40 nM
gamabufotalin) in the presence or absence of 5 mM SB203580,
a specific inhibitor of p38 MAPK. Consistent with the results in
Figure 3, exposure to the aforementioned combined regimen
significantly reduced cell viability by approximately 50% (Figure
7B). The efficacy of each combined regimen was significantly
intensified by the addition of SB203580, whereas the similar
phenomena were not observed by the addition of SB202474, a
negative control of SB203580 (Figure 7B), indicating the critical
role of p38 MAPK for cell survival. Moreover, neither SB203580
nor SB202474 itself affected the cell viability.A B
C D
FIGURE 3 | Synergistic cytotoxic effect of AsIII and gamabufotalin in U-87 but not in U-251 cells. (A) U-87 cells were treated with relatively high concentrations of
AsIII (3.3, 5, and 7.5 µM) and gamabufotalin (40, 60, and 90 nM), alone or in combination. (B) U-251 cells were treated with relatively high concentrations of AsIII (10
and 15 µM) and gamabufotalin (100 and 150 nM), alone or in combination. U-87 (C) and PBMCs (D) were treated with relatively low concentrations of AsIII (1 and 2
µM) and gamabufotalin (20 and 50 nM), alone or in combination. Following the aforementioned treatment for 48 h, cell viability was determined by XTT assay.
Relative cell viability was calculated as the ratio of the absorbance at 450 nm of each treatment group against those of the corresponding untreated control group.
Data are shown as the means ± SD (n ≥ 3). ∫p < 0.05; #p < 0.01; †p < 0.001; ♪p < 0.0001 vs. each alone. As, AsIII; Gama, gamabufotalin.TABLE 1 | CI values of the combination of relatively high concentrations of AsIII
and gamabufotalin in U-87 cells.
AsIII (mM) Gamabufotalin (nM) Fa CI value
3.3 40 0.52 0.77270
5 60 0.61 0.80496
7.5 90 0.69 0.86192CI < 1 represents synergism. As, AsIII; Fa, the effect levels; CI, combination index.TABLE 2 | CI values of the combination of relatively low concentrations of AsIII
and gamabufotalin in U-87 cells.
As (mM) Gamabufotalin (nM) Fa CI value
1 20 0.34 0.77496
1 50 0.42 0.87181
2 20 0.45 0.79036
2 50 0.49 0.90709CI < 1 represents synergism. As, AsIII; Fa, the effect levels; CI, combination index.March 2021 | Volume 11 | Article 628914
Yuan et al. Cytotoxicity of AsIII+Gamabufotalin in U-87Involvement of Autophagic Cell Death in
the Cytotoxicity of U-87 Cells Treated With
the Combination of AsIII and
Gamabufotalin
As shown in Figures 8A, B, compared to control group
and each single drug, a modest upregulation of theFrontiers in Oncology | www.frontiersin.org 8expression level of LC3, an autophagic marker, was clearly
induced by the treatment of 1 and 2 µM AsIII when combined
with 20 nM gamabufotalin, respectively. Furthermore, both 1
µM AsIII+50 nM gamabufotalin and 2 µM AsIII+50 nM
gamabufotalin significantly upregulated the expression level
of LC-3 in comparison to each single drug treatment, and theA
B
FIGURE 4 | Effects of relatively low concentrations of AsIII in combination with gamabufotalin on G2/M arrest and the expression level of cell cycle related-proteins in
U-87 cells. Following treatment for 48 h with AsIII (1 and 2 µM) and gamabufotalin (20 and 50 nM), alone or in combination, cell cycle profiling was performed by
FACSCanto flow cytometer as described under Materials and Methods. A total of 10,000 events were acquired, and FACSDiva™ software and ModFit LT™ v3.0
were used to calculate the number of cells at G2/M phase fraction (A). Results are shown as the means ± SD (n ≥ 3). After the same treatment, the expression
profiles of cell cycle-associated proteins were analyzed using western blotting. A representation image of the expression profile of each protein is shown from three
independent experiments (B). The expression levels were expressed as the ratios between each targeted protein and b-actin protein expression levels, and were
compared with those of control group. ∫p < 0.05; #p < 0.01; †p < 0.001; ♪p < 0.0001 vs. each alone. As, AsIII; Gama, gamabufotalin.March 2021 | Volume 11 | Article 628914
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greater potency.
Since induction of autophagy by various anticancer drugs has
been suggested to be a potential therapeutic strategy for cancer
including glioblastoma (42–46), wortmannin, a potent
autophagy inhibitor, was employed to further confirm whether
the induction of autophagy contributed to the combined
treatment-induced cell death. As shown in Figure 8C,Frontiers in Oncology | www.frontiersin.org 9following treatment with 2 mM AsIII plus 50 nM gamabufotalin
for 48 h, a significant decrease in cell viability was confirmed
again in U-87 cells. The addition of wortmannin, however,
significantly rescued the cell from toxicity caused by the
combined regimen in a dose-dependent manner. Moreover, the
cell viability was almost not altered by wortmannin alone.DISCUSSION
Results from this study clearly demonstrated that AsIII and
gamabufotalin exhibited cytotoxicity against glioblastoma cell
lines U-87 and U-251, and that U-87 cells were more sensitive to
the cytotoxicity of both drugs in comparison to U-251 cells
(Figure 1). Previous studies have demonstrated that U-87 cells
express wild type p53, known as a tumor suppressor, whereas U-
251 cells harbor p53 mutant (12, 44, 47). An intact p53 protein
function has been implicated in the cytotoxicity of As2O3 in
glioblastoma cells as evidenced by the fact that U-87 cells were
more susceptible to the drug than T98G, another glioblastoma
cell line harboring p53 mutant (12). Collectively, the p53 status
could be attributed to the differential susceptibility of U-87 and
U-251 cells to either AsIII or gamabufotalin, although further
studies will be needed to clarify whether both drugs affect the
expression and function of p53 in these cells.
Our cell cycle analysis results further demonstrated that a
dose-dependent biphasic effect of AsIII on G2/M arrest was
interestingly observed in U-87 cells, in which G2/M arrest-
inducing activity of AsIII was observed at the concentrationFIGURE 5 | Enhanced LDH release in U-87 cells treated with relatively low
concentrations of AsIII combined with gamabufotalin. Following treatment for
48 h with AsIII (1 and 2 µM) and gamabufotalin (20 and 50 nM), alone or in
combination, LDH leakage was measured using the LDH-Cytotoxic test kit as
described under Materials and methods. Results are shown as the means ± SD
(n ≥ 3). #p < 0.01; ♪p < 0.0001 vs. each alone. As, AsIII; Gama, gamabufotalin.FIGURE 6 | Effect of relatively high concentrations of AsIII and gamabufotalin on the expression level of phospho-p38 and its total form in U-87 cells. Following
treatment for 48 h with various concentrations of AsIII (3.3, 5, 7.5 µM) and gamabufotalin (40, 60, 90 nM), alone or in combination, the expression profiles of
phospho-p38 (p-p38) and p38 were analyzed using western blotting. A representation image of the expression profile of each protein is shown from three
independent experiments. The expression levels were expressed as the ratios between each targeted protein and b-actin protein expression levels, and were
compared with those of control group. A p value less than 0.05 was considered as statistically significant (#p < 0.01 vs. each alone). As, AsIII; Gama, gamabufotalin.March 2021 | Volume 11 | Article 628914
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concentrations of 3 mM AsIII, then declined with increasing
concentrations of AsIII (Figure 2A). In comparison, a marked
G2/M arrest along with sub-G1 peak, known as a hallmark of
apoptosis, was concomitantly observed in U-251 cells following
the exposure to relatively high concentrations of AsIII (20 and 30
mM) (Figure 2B and Supplementary Figure 2), suggesting that
besides G2/M arrest, apoptosis induction is also implicated in the
cytotoxicity of AsIII in the cells. In fact, previous reports have
demonstrated that As2O3 inhibited the growth of glioblastoma
cell lines including U-87 and U-251 via apoptosis induction as
well as G2/M arrest (12–14). Considering the higher
susceptibility of U-87 cells to AsIII, we hypothesized that the
drop in the G2/M population caused by >3 mMAsIII and the lack
of sub-G1 peak might be due to a loss of a portion of damaged
cells, which probably turned into dead cell debris and were too
small to be detected, as a result of intensive cytotoxicity of AsIII.
The hypothesis testing and further studies on whether apoptosis
induction occurs and links to cell cycle arrest in both U-87 andFrontiers in Oncology | www.frontiersin.org 10U-251 cells treated with AsIII and gamabufotalin, alone or in
combination, are ongoing in our laboratory. In the current study,
instead of focusing on the mechanisms underlying the biphasic
effect of AsIII on G2/M arrest in U-87 cells, a promising result
showing that G2/M arrest was significantly induced by clinically
achieved concentrations of AsIII (1 and 2 mM) encouraged us to
explore the effects of the relatively low concentrations of AsIII in
combination with gamabufotalin against U-87 cells as
mentioned below.
Active bufadienolide compounds, including bufalin,
arenobufagin and hellebrigenin, have been demonstrated to
induce G2/M arrest in U-87 or U-251 (19, 24, 48). In line with
thesepreviousfindings, treatmentwithgamabufotalin causedG2/M
arrest in both two cells (Figures 2C, D, Supplementary Figures 3
and 4). Of note, theG2/Marrest-inducing activity of gamabufotalin
was more potent in U-87 compared to that in U251 as evidence by
the fact that G2/M arrest already reached a plateau at the
concentrations of 100 nM gamabufotalin in U-87 cells, whereas a
clear G2/M arrest just began to appear at the same concentration inA
B
FIGURE 7 | Prosurvival role of p38 MAPK in the cytotoxicity of U-87 cells treated with the combination of AsIII and gamabufotalin. (A) Following treatment for 48 h
with relatively low concentrations of AsIII (1, 2 µM) and gamabufotalin (20, 50 nM), alone or in combination, the expression profiles of phospho-p38 (p-p38) and p38
were analyzed using western blotting. A representation image of the expression profile of each protein is shown from three independent experiments. The expression
levels were expressed as the ratios between each targeted protein and b-actin protein expression levels, and were compared with those of control group.
(B) Following treatment for 48 h with the combined regimen of 2 µM AsIII + 50 nM gamabufotalin; 3.3 µM AsIII + 40 nM gamabufotalin, in the presence of absence of
5 µM SB203580, a specific inhibitor for p38 MAPK and its negative control SB202474, cell viability was determined by XTT assay. Relative cell viability was
calculated as the ratio of the absorbance at 450 nm of each treatment group against those of the corresponding untreated control group. Data are shown as the
means ± SD (n ≥ 3). A p value less than 0.05 was considered as statistically significant (§p < 0.001; ‡p < 0.0001 vs. control. $p < 0.001 vs. As+Gama and As+Gama+
SB202474). As, AsIII; Gama, gamabufotalin; SB203, SB203580; SB202, SB202474.March 2021 | Volume 11 | Article 628914
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These results thus reconfirmed the higher susceptibility of U-87
cells to gamabufotalin, and further suggested that the G2/M arrest
play a critical role in the cytotoxicityofbothAsIII andgamabufotalin
in both cancer cells.
It is noteworthy that like the treatment with relatively high
concentrations of AsIII (3.3, 5, 7.5 mM) and gamabufotalin (40,
60, 90 nM) (Figure 3A, Table 1), synergistic cytotoxic effects of
clinically achieved concentrations of AsIII (1, 2 mM) and
gamabufotalin (20, 50 nM) were also successfully observed in
U-87 cells (Figure 3C, Table 2). Most importantly, the same
regimen was much less cytotoxic to PBMCs (Figure 3D),
suggesting the selective cytocidal effects of the combined
regimen and its possible beneficial effect in patient with
glioblastoma. Moreover, enhanced G2/M arrest was observed
in U-87 cells treated with the combined regimen of relatively low
concentrations of AsIII (1, 2 mM) and gamabufotalin (20, 50 nM),
accompanied by a downregulation of cdc25C and Cyclin B1/cdc2
as well as survivin (Figure 4 and Supplementary Figure 5).
Several lines of evidence have demonstrated that in glioblastoma
cell lines such as U-87 and U-251, downregulation of the
expression levels of Cyclin B1 and cdc2 has been implicated in
the G2/M arrest induced by various anticancer agents, including
As2O3 (12, 14), active bufadienolide compounds such asFrontiers in Oncology | www.frontiersin.org 11hellebrigenin (19) and geldanamycin, an inhibitor of the
chaperone activity of heat shock protein 90 (Hsp90) (49).
Survivin is highly expressed in most human cancer cells
including primary human glioblastoma cells (19, 30), and its
inhibition has been considered as a compelling strategy for
cancer therapy (50). Moreover, the expression of survivin has
been suggested to be a useful biomarker for predicting the
prognosis in glioblastoma patients (51). Previous studies have
demonstrated that survivin expression peaks in the G2/M phase
and rapidly declines in the G1 phase, and that survivin can be
phosphorylated by cdc2 (50). In fact, our previous results have
reported that exposure to active bufadienolide compounds
including gamabufotalin resulted in the downregulation of
survivin expression along with G2/M arrest in U-87 cells (19,
36). Taken together, these results suggested that G2/M arrest
associated with downregulation of cdc25C, Cyclin B1/cdc2 and
survivin largely contributed to the cytotoxic effect of AsIII and
gamabufotalin even at their relatively low concentrations.
Of note, LDH leakage was also induced by relatively low
concentrations of AsIII and gamabufotalin, and was further
augmented by their combination, especially 2 mM AsIII combined
with 20 and 50 nM gamabufotalin, respectively (Figure 5).
Similarly, a previous report demonstrated that AsIII induced
necrosis through a regulated, Bcl-xL-sensitive mitochondrialA
B C
FIGURE 8 | Involvement of autophagic cell death in the cytotoxicity of U-87 cells treated with the combination of AsIII and gamabufotalin. Following treatment for
48 h with AsIII (1, 2 µM) and gamabufotalin (20, 50 nM), alone or in combination, the expression profiles of LC3 were analyzed using western blotting. A
representation image of the expression profile of LC3 is shown from three independent experiments (A). The expression levels were expressed as the ratio between
LC3 protein and b-actin protein expression levels, and were compared with those of control group (B). Cell viability was determined by XTT assay after treatment for
48 h with the combination of 2 µM AsIII and 50 nM gamabufotalin in the presence or absence of wortmannin (0.25, 1 µM) (C). Data are shown as the means ± SD
(n ≥ 3). A p value less than 0.05 was considered as statistically significant (∫p < 0.05 vs. each alone; *p < 0.05; ‡p < 0.0001 vs. control; †p < 0.05; #p < 0.0001 vs.
As+Gama). As, AsIII; Gama, gamabufotalin.March 2021 | Volume 11 | Article 628914
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enhancement in G2/M arrest was observed in the combination of 2
mM AsIII plus 20 or 50 nM gamabufotalin in comparison to each
single drug (Figure 4A), the synergistic cytocidal effect of the
combined regimen could be attributed to both G2/M arrest and
LDH leakage.
Intriguingly, previous studies have demonstrated a prosurvival
role for p38 MAPK in glioblastoma cells, including U-87 cells (19,
36, 53). Furthermore, phosphorylation of p38 MAPK has been
suggested to be a prognostic marker for patients with high-grade
glioma, and vandetanib combined with a p38MAPK inhibitormay
be a useful combination chemotherapy for patients with glioma
(35). In line with these previous findings, activation of p38 MAPK
pathway was observed in U-87 cells following treatment with AsIII
and gamabufotalin, alone or in combination, as evidenced by a clear
increase in the expression level of phopho-p38, although the
magnitude of increase was dependent on drug concentrations
(Figures 6 and 7). Our results further demonstrated that the
addition of a specific inhibitor of p38 MAPK enhanced the
cytotoxicity of the combination of AsIII and gamabufotalin,
reconfirming its prosurvival role in the cells (Figure 7B). Taking
the previous results and our observations into account, we thus
hypothesized that combining a p38 MAPK inhibitor with the
combined regimen of AsIII and gamabufotalin may further
improve the efficacy of these drugs, and may provide more
therapeutic benefits to patients with glioblastoma, although the
precise contribution of the p38 MAPK pathway warrants further
investigation invitro and invivo. Inaddition, onlymodest induction
ofp38MAPKactivationby the clinically achieved concentrations of
AsIII in combinationwith gamabufotalin suggest that the combined
regimen should be beneficial to avoid activating the prosurvival
pathway in glioblastoma cells.
Induction of autophagic cell death by various chemotherapeutic
agents has also considered as a potential therapeutic strategy for
cancer (13, 43–45). In the current study, the autophagic cell death
was confirmed by the significant upregulation of LC-3, an
autophagic marker, in U-87 cells treated with the combined
regimen of AsIII and gamabufotalin (Figures 8A, B). The
cytotoxicity of combined regimen was further significantly
abrogated by the addition of wortmannin, a potent autophagy
inhibitor (27, 41), in a dose-dependent manner (Figure 8C). In
line with these current findings, autophagic cell death has been
implicated in the cytotoxicity of As2O3 against several types of
glioblastoma cells (13, 43, 45). Several research groups including us
have also demonstrated that a number of bufadienolides such as
bufalin, arenobufagin and gamabufotalin induce autophagy in
numerous cancer cells including glioblastoma cells (36, 54, 55).
Collectively, our results suggested for the first time that besides
G2/M arrest and necrosis, autophagic cell death also partially
contributed to cytotoxicity of the combined regimen of AsIII
and gamabufotalin.
Interestingly, Yoshimura and colleagues have demonstrated
that As2O3 sensitizes glioblastoma to a Myc inhibitor-mediated
growth inhibition, based on a study using patient-derived
glioblastoma cancer stem-like cells and its xenograft model
(56). Although gamabufotalin has been identified as anFrontiers in Oncology | www.frontiersin.org 12inhibitor of c-Myc in myeloma cell lines (57), our previous
study demonstrated that treatment with gamabufotalin almost
had no effect on the expression of c-Myc in U-87 cells (36). Given
that c-Myc may serve as one of the candidate targets of cancer
therapy (58, 59), future studies on how AsIII in combination with
gamabufotalin affects the c-Myc expression profile in a mouse
xenograft model of human glioblastoma are warranted.CONCLUSION
Our results demonstrated that U-87 cells were highly susceptible
to both AsIII and gamabufotalin, alone or in combination, in
comparison to U-251 cells. We further demonstrated that
clinically achieved concentrations of AsIII combined with
gamabufotalin exhibited synergistic cytotoxic effect against U-
87 cells, whereas showed much less cytotoxic to PBMCs,
suggesting that the combined regimen could provide possible
beneficial effect in patient with glioblastoma with high potency,
selectivity and tolerability. G2/M arrest, necrosis as well as
autophagic cell death induction appeared to cooperatively
contribute to the synergistic cytotoxicity of AsIII combined
with gamabufotalin. Given that p38 MAPK serves an essential
role in promoting glioblastoma cell survival, developing a
possible strategy composed of AsIII, gamabufotalin and a p38
MAPK inhibitor with the aim of preventing the activation of the
p38 MAPK pathway may provide novel insight into approaches
designed to treat glioblastoma. Furthermore, the capacity of
gamabufotalin to cross the blood-brain barrier is also of great
concern and must warrant further investigation.DATA AVAILABILITY STATEMENT
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